Shares of Moderna (MRNA.US) experienced a significant increase on Thursday as it reported a surprising profit and surpassed Wall Street’s quarterly forecasts. The Covid vaccine producer announced earnings of $0.55 per share on $2.8 billion in revenue for the fourth quarter, shattering FactSet analysts’ predictions of a $0.99 per share loss on $2.5 billion in sales. 

According to Chief Financial Officer Jamey Mock, this unexpected earnings result is partially due to a $600 million deferral in revenue. In a promising turn of events, Moderna continues to deliver on its pledge to trim its expenses. The expense for goods sold over the past year was noted to be $4.7 billion, undercutting the estimated figure of $5 billion. Nonetheless, the firm’s sales during the fourth quarter underwent a 45% reduction on a year-on-year basis, a dip largely attributed to the decreased sales of the company’s Covid-19 vaccine, as stated in Moderna’s press release. Correspondingly, the earnings also faced an 85% downfall. 

For the entire 2023, Moderna disclosed revenues of $6.8 billion, which is a 64% decrease when compared with the previous year, and a per-share loss of $12.33, a stark contrast to the $20.12 earnings per share registered in 2022. 

Moderna is currently seeking new opportunities by focusing on its mRNA technology for developing other pharmaceuticals, which include a respiratory syncytial virus (RSV) vaccine that is ready to challenge vaccines from two leading competitors — Pfizer (PFE.US) and GSK (GSK.US). 

Moderna stock jumped 13.5% to 99.44, following earnings releases. As for prospects, Moderna reaffirmed its forecast of $4 billion in sales for 2024, accompanied by research and development costs amounting to $4.5 billion. 

(Moderna Stock Performance One-year Chart) 

Disclaimer  

Comments, news, research, analysis, price, and all information contained in the article only serve as general information for readers and do not suggest any advice. Ultima Markets has taken reasonable measures to provide up-to-date information, but cannot guarantee accuracy, and may modify without notice. Ultima Markets will not be responsible for any loss incurred due to the application of the information provided. 

marketing

See Full Bio